Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy source : Www.prnewswire.com save search
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.17%
H: 1.41%
C: -0.22%
t-cell for therapy growth market
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 11:00) - prnewswire.com
VSTM | $9.86 -3.62% -3.75% 150K
|
Health Technology
|
| O: 5.64%
H: 1.41%
C: -2.89%
gfh375 meeting therapeutics potential therapy
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Published: 2024-04-06 (Crawled : 04:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
carvykti fda first approved one treatment for therapy
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Published: 2024-04-03 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.76%
H: 13.15%
C: 7.61%
reqorsa lung cancer treat cell trial therapy study
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Published: 2024-04-02 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: -5.72%
H: 7.14%
C: 1.43%
oncoprex positive system preclinical therapy
Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.28%
H: 0.27%
C: 0.04%
cancer therapy
Global Continuous Renal Replacement Therapy (CVVH, CVVHDF, CVVHD, SCUF) Industry Research 2024-2033
Published: 2024-03-29 (Crawled : 18:00) - prnewswire.com
CTSO | $0.8026 0.2% 0.2% 46K
|
Health Technology
| Email alert
Add to watchlist
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
| Email alert
Add to watchlist
renal research global therapy
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
Published: 2024-03-28 (Crawled : 11:00) - prnewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -0.97%
H: 1.18%
C: -0.98%
gfh009 brukinsa cell collaboration trial therapy study
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
Published: 2024-03-28 (Crawled : 11:00) - prnewswire.com
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.68%
H: 0.4%
C: -5.64%
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: -0.6%
H: 4.22%
C: -7.83%
rgx-314 lancet publication therapy study
Global Particle Therapy Market Analysis and Forecasts, 2023-2033 : Revolutionizing Cancer Treatment, Particle Therapy's Rise in External Beam Radiotherapy
Published: 2024-03-27 (Crawled : 23:00) - prnewswire.com
BSGM | $1.41 -8.44% -9.22% 200K
|
Health Technology
|
| O: 3.94%
H: 4.19%
C: -10.55%
cancer global therapy market
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
Published: 2024-03-22 (Crawled : 23:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
opsynvi fda first hypertension therapy
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Published: 2024-03-19 (Crawled : 20:00) - prnewswire.com
PSTX | News | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: -1.03%
H: 6.94%
C: 3.13%
conference cell therapeutics therapy
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Published: 2024-03-12 (Crawled : 13:00) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: -1.49%
H: 0.0%
C: -9.07%
reqorsa patent treat grant therapy
US FDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy
Published: 2024-03-07 (Crawled : 08:00) - prnewswire.com
PPRUF | News | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -1.57%
H: 1.91%
C: 0.49%
PPRUY | News | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -0.6%
H: 1.23%
C: 1.17%
fda drug cancer designation grants therapy
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-03-06 (Crawled : 13:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 24.27%
H: 5.66%
C: -14.45%
reqorsa lung positive treatment system preclinical meeting therapy
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
rybrevant fda first lung approved cancer cell treatment therapy
Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024: PRMT5 Targeted Therapies Clinical Trials by Company, Indication & Phase
Published: 2024-02-28 (Crawled : 23:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.56%
H: 0.12%
C: -0.38%
trials global therapy market
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Published: 2024-02-26 (Crawled : 12:30) - prnewswire.com
ATNM | $6.85 2.7% 0.0% 350K
|
Health Technology
|
| O: 2.04%
H: 19.98%
C: 18.71%
astct active aml trial therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.